Health ❯ Clinical Research

Drug Efficacy

Clinical Trials Side Effects Phase Trials Patient Outcomes Weight Loss Studies Cirrhosis Treatment Muscle Preservation Binding Affinity Alcohol Consumption Weight Loss

Deloitte Warns GLP-1 Boom Is Inflating Pharma Returns, Concentrating Risk

Heavy bets on obesity drugs increase vulnerability to shocks.

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

Brazil Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Celebrities Put Propranolol in the Spotlight as Off-Label Anxiety Aid

Wegovy Becomes First GLP-1 Therapy Approved by FDA for MASH

WHO Recommends Six-Monthly Lenacapavir Injection for HIV Prevention

AstraZeneca’s Baxdrostat Delivers Significant Blood Pressure Reductions in Phase 3 Trial for Resistant Hypertension

Albumin-PLGA Nanoparticles Enable Ultrahigh Drug Loading and Six-Month Stability

Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Novo Nordisk Launches Wegovy in France Without Reimbursement